Rotavirus

From Free net encyclopedia

(Redirected from RV-E)
Rotaviruses
Image:Rotavirus.jpg

Template:Taxobox begin placement virus Template:Taxobox group iii entry

Family:Reoviridae
Genus:Rotavirus

|- style="text-align:center; background:violet;" !Species |- | style="padding: 0 .5em;" | Rotavirus A (RV-A)
Rotavirus B (RV-B)
Rotavirus C (RV-C)
Rotavirus D (RV-D)
Rotavirus E (RV-E)
Rotavirus F (RV-F)
Rotavirus G (RV-G)
|} Rotaviruses are a genus of viruses belonging to the Reoviridae family. Seven major groups have been identified, three of which (groups A, B, and C) infect humans, with group A being the most common and widespread one. They cause vomiting and diarrhea and are the most common cause of severe diarrhea in children, killing about 600,000 children every year in developing countries (as of 2005). New vaccines have been shown to be safe and effective in 2006.

Contents

Structure of the viruses

Rotaviruses have a genome consisting of 11 double-stranded RNA segments surrounded by a distinctive three-layered icosahedral protein capsid. The first layer is formed by the protein VP2, with each vertex having a copy of the proteins VP1 and VP3. The second layer is formed by the protein VP6. The outermost protein layer is composed of the structural glycoprotein VP7 and the spike protein VP4. Viral particles are up to 100 nm in diameter and have a buoyant density of 1.36 g/ml in CsCl.

Nature of acute disease

Rotaviruses cause acute gastroenteritis. "Infantile diarrhea", "winter diarrhea", "stomach flu", "acute nonbacterial infectious gastroenteritis", and "acute viral gastroenteritis" are other names applied to this disease.

Rotavirus gastroenteritis is a self-limiting, mild to severe disease characterized by vomiting, watery diarrhea, and low-grade fever. The infective dose is presumed to be 10-100 infectious viral particles. Because a person with rotavirus diarrhea often excretes large numbers of virus (108-1010 infectious particles/ml of feces), infection doses can be readily acquired through contaminated hands, objects, or utensils. Asymptomatic rotavirus excretion has been well documented and may play a role in perpetuating endemic disease.

The virus infects enterocytes of the villi of the small intestine, leading to structural changes of the epithelium and diarrhea.

The incubation period ranges from 1-3 days. Symptoms often start with vomiting followed by 4-8 days of diarrhea. Temporary lactose intolerance may occur. Recovery is usually complete. However, severe diarrhea without fluid and electrolyte replacement may result in death. Childhood mortality caused by rotavirus is relatively low in the U.S., with an estimated 100 cases/year, but reaches over 500,000 cases/year worldwide (as of 2005). Association with other enteric pathogens may play a role in the severity of the disease.

Target populations and frequency

Humans of all ages are susceptible to rotavirus infection. Children 6 months to 2 years of age, premature infants, the elderly, and the immunocompromised are particularly prone to more severe symptoms caused by infection with group A rotavirus.

Group A rotavirus is endemic worldwide. It is the leading cause of severe diarrhea among infants and children, being responsible for about 20% of cases, and accounts for about half of the cases requiring hospitalization. Almost every child has been infected with rotavirus by age 5. Over 3 million cases of rotavirus gastroenteritis occur annually in the U.S. In temperate areas, it occurs primarily in the winter, but in the tropics it occurs throughout the year. The number attributable to food contamination is unknown.

Group B rotavirus, also called adult diarrhea rotavirus or ADRV, has caused major epidemics of severe diarrhea affecting thousands of persons of all ages in China.

Group C rotavirus has been associated with rare and sporadic cases of diarrhea in children in many countries. However, the first outbreaks were reported from Japan and England.

About 120 million rotavirus infections occur every year, causing the death of 600,000 to 650,000 children.

Diagnosis of human illness

Specific diagnosis of the disease is made by identification of the virus in the patient's stool. Enzyme immunoassay (EIA) is the test most widely used to screen clinical specimens, and several commercial kits are available for group A rotavirus. Electron microscopy and polyacrylamide gel electrophoresis are used in some laboratories in addition or as an alternative to EIA. A reverse transcription-polymerase chain reaction (RT-PCR) has been developed to detect and identify all three groups of human rotaviruses.

Transmission and associated foods

Rotaviruses are transmitted by the fecal-oral route. Person-to-person spread through contaminated hands is probably the most important means by which rotaviruses are transmitted in close communities such as pediatric and geriatric wards, day care centers and family homes.

Infected food handlers may contaminate foods that require handling and no further cooking, such as salads, fruits, and hors d'oeuvres. Rotaviruses are quite stable in the environment and have been found in estuary samples at levels as high as 1-5 infectious particles/gal. Sanitary measures adequate for bacteria and parasites seem to be ineffective in endemic control of rotavirus, as similar incidence of rotavirus infection is observed in countries with both high and low health standards.

The virus has not been isolated from any food associated with an outbreak, and no satisfactory method is available for routine analysis of food. However, it should be possible to apply procedures that have been used to detect the virus in water and in clinical specimens, of which reverse transcription (RT)-PCR amplification is the most sensitive method to food analysis.

Vaccines

In 2006, two vaccines against Rotavirus infection were shown to be safe and effective in children: Rotarix by GlaxoSmithKline and RotaTeq by Merck. Both are taken orally and contain disabled live virus. In February 2006, the U.S. Food and Drug Administration approved RotaTeq for use in the United States. Merck announced a price of $187.50 for the standard three-dose regimen; this is much more expensive than other standard childhood immunizations and, even allowing for discounts, will probably prevent widespread use of the vaccine in poor countries.

An earlier vaccine, Rotashield by Wyeth-Ayerst, had to be taken off the market in the late 1990s after rare but severe side effects were discovered. These complications were so rare that widespread adoption of Rotashield in developing countries would nevertheless have saved millions of lives, but use of a vaccine deemed unsafe in the U.S. was seen as unacceptable.

Selected outbreaks

Literature references can be found at the links below.

MMWR 48(27):1999 On August 31, 1998, a tetravalent rhesus-based rotavirus vaccine (RotaShield[Registered]*, Wyeth Laboratories, Inc., Marietta, Pennsylvania) (RRV-TV) was licensed in the United States for vaccination of infants. The Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics, and the American Academy of Family Physicians have recommended routine use of RRV-TV for vaccination of healthy infants (1,2). During September 1, 1998-July 7, 1999, 15 cases of intussusception (a bowel obstruction in which one segment of bowel becomes enfolded within another segment) among infants who had received RRV-TV were reported to the Vaccine Adverse Event Reporting System (VAERS).

Outbreaks of group A rotavirus diarrhea are common among hospitalized infants, young children attending day care centers, and elder persons in nursing homes. Among adults, multiple foods served in banquets were implicated in 2 outbreaks. An outbreak due to contaminated municipal water occurred in Colorado, 1981.

Several large outbreaks of group B rotavirus involving millions of persons as a result of sewage contamination of drinking water supplies have occurred in China since 1982. Although to date outbreaks caused by group B rotavirus have been confined to mainland China, seroepidemiological surveys have indicated lack of immunity to this group of virus in the U.S.

The newly recognized group C rotavirus has been implicated in rare and isolated cases of gastroenteritis. However, it was associated with three outbreaks among school children: one in Japan, 1989, and two in England, 1990.

MMWR 47(45):1998 In August 1998, the first live attenuated rotavirus vaccine (Rotashield{registered} {Wyeth Lederle Vaccines and Pediatrics}) was approved for use in infants by the Food and Drug Administration. The Advisory Committee on Immunization Practices has recommended that this vaccine be given as a three-dose schedule to infants aged 2, 4, and 6 months. Since 1991, rotavirus activity in the United States has been prospectively monitored by the National Respiratory and Enteric Virus Surveillance System (NREVSS), a voluntary, laboratory-based system. This report summarizes surveillance data from NREVSS during the 1997-1998 rotavirus season and reviews issues related to rotavirus surveillance that are important for a national rotavirus vaccine program.

MMWR 47(19):1998 On June 24, 1996, the Livingston County (New York) Department of Health (LCDOH) was notified of a cluster of diarrheal illness following a party on June 22, at which approximately 30 persons had become ill. This report summarizes the findings of the investigation, which implicated a deficient water supply system as the cause of an outbreak of diarrheal illness caused by Salmonella serotype Hartford and P. shigelloides. Unfiltered, untreated surface water led to contamination of food during its preparation.

MMWR 40(5)1991 A discussion of rotavirus surveillance in the US.

For more information on recent outbreaks see the CDC Morbidity and Mortality Weekly Reports.

Sources

External links

de:Rotaviren es:Rotavirus fr:Rotavirus ja:ロタウイルス lt:Rotavirusinė infekcija pl:Rotawirusy pt:Rotavirus zh:輪狀病毒